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Abstract: We analyzed the secretory dynamics of tissue plasminogen activator (tPA) in 
EA.hy926 cells, an established vascular endothelial cell (VEC) line producing GFP-tagged 
tPA, using total internal reflection fluorescence (TIR-F) microscopy. tPA-GFP was 
detected in small granules in EA.hy926 cells, the distribution of which was 
indistinguishable from intrinsically expressed tPA. Its secretory dynamics were unique, 
with prolonged (>5min.) retention of the tPA-GFP on the cell surface, appearing as 
fluorescent spots in two-thirds of the exocytosis events. The rapid disappearance (mostly 
by 250ms) of a domain-deletion mutant of tPA-GFP possessing only the signal peptide and 
catalytic domain indicates that the amino-terminal heavy chain of tPA-GFP is essential 
for binding to the membrane surface. The addition of PAI-1 dose-dependently facilitated 
the dissociation of membrane-retained tPA and increased the amounts of tPA-PAI-1 high 
molecular weight complexes in the medium. Accordingly, suppression of PAI-1 synthesis 
in EA.hy926 cells by siRNA prolonged the dissociation of tPA-GFP, whereas a catalytically 
inactive mutant of tPA-GFP not forming complexes with PAI-1 remained on the 
membrane even after PAI-1 treatment. Our results provide new insights into the 
relationship between exocytosed, membrane-retained tPA and PAI-1, which would 
modulate cell surface–associated fibrinolytic potential. 
Introduction 
Tissue plasminogen activator (tPA) is a 68kDa serine protease that cleaves a single 
peptide bond in plasminogen to generate plasmin, which subsequently dissolves fibrin 
clots in the vasculature.1 The expression of its activity is finely-tuned by the amount of its 
specific inhibitor, plasminogen activator inhibitor-1 (PAI-1),2,3 which is present in molar 
excess over tPA in human plasma. Thus, only a relatively small fraction of tPA circulates 
in blood in a functionally active form. Therefore, not only an elevation of plasma 
concentration of PAI-1 but an impairment of tPA-release results in decreased fibrinolytic 
activity, which is regarded as a risk factor for ischemic cardiovascular events.4-6 Although 
the enzymological interactions of these two molecules in the fluid phase have been 
extensively studied, interactions at the interface between fluid-phase and solid-phase 
structures such as fibrin and the cell surface where functional fibrinolysis actually takes 
place are not fully elucidated.7 
   In blood, tPA is primarily secreted from vascular endothelial cells (VECs) as an active 
single-chain enzyme,8 in contrast to most other serine proteases involved in coagulation 
and fibrinolysis, which are secreted as zymogens. Facilitated secretion, therefore, is 
directly related to the enhancement of fibrinolytic activity, which protects the VEC 
surface from clot accumulation and maintains vascular patency. Clinically, impairment of 
acute tPA release is reported in atherosclerosis, hypertension and cigarette smoking.9-12 
VECs secrete tPA through both constitutive and regulated pathways13-17 from small 
secretory granules morphologically distinct from the larger Weibel-Palade bodies.18 
Although the precise signaling pathways regulating tPA release have not been elucidated, 
G-protein-coupled activation and increased intracellular calcium signaling appears to be 
important.15,17 
   Recent advances in the use of fluorescent proteins, such as green fluorescent protein 
(GFP), have allowed us to visualize cellular events and cellular components in intact, 
living cells by monitoring fluorescence intensity and its localization within the cell. 
Several studies,19-21 mainly in excitable cells, employed GFP-tagged secretory molecules 
to document in detail the dynamics of their release from their granules, using total 
internal reflection-fluorescence (TIR-F) microscopy. This technique employs 
evanescent-wave excitation only of the fluorophore present in the immediate vicinity of 
the plasma membrane.  
   Using a similar approach, we conducted the present study to analyze the exocytotic 
dynamics of tPA in VECs under non-stimulated conditions. Slow secretory kinetics of 
tPA-GFP were demonstrated in VECs that exocytosed tPA-GFP molecules which are 
retained at the site on the cell membrane where the granules opened, and for which the 
amino-terminal heavy chain of tPA was required. Furthermore, PAI-1 appears to facilitate 
the dissociation of membrane-retained tPA, which would therefore decrease cell 
surface-associated fibrinolytic potential. These results provide new insights into the 
functional interactions of tPA and PAI-1 on the VEC surface. 
 
Materials and Methods 
Plasmid construction 
The cDNA fragment encoding the enhanced green fluorescent protein (EGFP) from 
pEGFP-N1 (Clontech) was subcloned into NheI/NotI sites of the pcDNA3.1(+) expression 
vector and designated GFP3.1. Total RNA from EA.hy926 cells was amplified by reverse 
transcription-PCR using the forward primer for the cDNA fragment encoding full-length 
human tPA excluding the stop codon (1686bp) 5’-TT GCT AGC ATG GAT GCA ATG AAG 
AGA GGG-3’ and the reverse primer 5’-T TGG ATC CTT CGG TCG CAT GTT GTC ACG 
AAT-3’. The PCR product was digested with NheI and BamHI and then subcloned into 
NheI/BamHI sites in GFP3.1 (tPA-GFP). A mutant tPA containing a Ser-to-Ala 
substitution at amino acid position 478 (tPA-S478A-GFP) was produced using tPA-GFP as 
a template and a QuikChange II site-directed mutagenesis kit (Stratagene, CA). The 
forward and reverse primers were 5’-GCC TGC CAG GGC GAT GCG GGA GGC CCC CTG 
GTG-3’ and 5’-CAC CAG GGG GCC TCC CGC ATC GCC CTG GCA GGC-3’, respectively. 
A deletion mutant tPA-GFP (tPA-CD-GFP) was generated using a simple and rapid 
method by PCR.22 A pair of primers, 5’-ACC TGC GGC CTG AGA CAG TAC-3’ and 5’-TTG 
GTA AGA TCT GGC TCC TCT-3’, was prepared for deleting tPA nucleotide position 
115-891 corresponding to amino acid position Val4-Ser262 (finger, epidermal growth 
factor-like, kringle 1, and kringle 2 domains; collectively FnEK1K2 domains, the so-called 
heavy chain).23 All plasmid vectors were sequenced and prepared under endotoxin-free 
conditions. 
 
Cell culture and transfection 
The human vascular endothelial cell line EA.hy926 was kindly provided by Dr. Edgell.24 
This cell line resembles cultured human VECs and has been shown to retain endothelial 
cell-specific functions in most respects, including their fibrinolytic characteristics.25 We 
cultured the cells in DMEM (Sigma) supplemented with glucose at 4.5 g/l and 10% fetal 
bovine serum at 37°C and 5% CO2 in a humidified atmosphere. For fluorescence imaging, 
the cells were cultivated on a 35-mm glass bottom dish (Asahi Techno Glass Co., Tokyo, 
Japan) and transfected with the plasmids by lipofection using TransITTM-LT1 (Mirus, 
Madison, WI) at 100% confluence. Experiments were performed within 2 days of transient 
transfection.  
 
Suppression of PAI-1 synthesis 
Cells were grown to 80-90% confluence in 35-mm glass bottom dishes and transfected 
with 20nM siRNA for PAI-1 #1: 5’ GUC ACA UUG CCA UCA CUC UTT (Sigma), #4: 5’ 
AAG CAC AAC UCC CUU AAG GUC TT 26 or siPerfect negative control (Sigma) using the 
N-TERTM Nanoparticle siRNA Transfection System (Sigma).  
 
Solutions and materials 
A Hepes-buffered solution (HBS) composed of 140mM NaCl, 5mM KCl, 1mM MgCl2, 
2.5mM CaCl2, 10mM glucose, and 10mM Hepes-NaOH (pH7.3) was employed in all 
imaging studies unless otherwise noted. In some experiments, 50mM NaCl was replaced 
by 50mM NH4Cl. Low pH solution (pH5.5) was buffered with Mes in place of Hepes. 
Human recombinant PAI-1 was purified as previously described.27 Human recombinant 
single chain tPA (sc-tPA) was kindly provided by Daiich Seiyaku (Tokyo, Japan). Human 
Glu-plasminogen was purified from freshly frozen human plasma by affinity 
chromatography on lysine-Sepharose. Human thrombin was from Benesis Co. (Osaka, 
Japan). Human fibrinogen and receptor-associated protein (RAP) were purchased from 
Enzyme Research Laboratories (South Bend, IN) and Calbiochem (Darmstadt, Germany), 
respectively. Anti-GFP and anti-GFP conjugated with tetramethylrhodamine 
isothiocyanate (TRITC) were from Molecular Probes (OR, USA) and Acris Antibodies 
GmbH (Hiddenhausen, Germany), respectively. Anti-tPA and anti-PAI-1 were produced in 
rabbits using human recombinant sc-tPA or PAI-1; the IgG fractions were isolated from 
the antiserum.  
 
Imaging experiments 
We employed a TIR-F microscopy unit for selective excitation only near the plasma 
membrane and its associated granules.28,29 Cells were imaged with an inverted 
microscope (IX71, Olympus) equipped with a 1.45 numerical aperture objective (60×, oil 
immersion, for TIRFM, Olympus) to generate the so-called ‘evanescent field’. The 
evanescent wave selectively excites fluorophores within 100nm of the glass-water 
interface. To reduce the bleaching of fluorophores and laser-derived cell damage, we 
introduced neutral density filters (Edmund Optics, Japan) to reduce laser intensity to 
12.5%. Bleaching of intracellular fluorophore was then suppressed to <10% by using ND 
filters. GFP was excited at 488nm, and the emitted light was collected. In some 
experiments, both GFP and TRITC were excited at 488nm, and the light emitted was 
collected through an emission splitter (W-View system, Hamamatsu Photonics, 
Hamamatsu, Japan) equipped with a 550nm dichroic mirror and two emission filters, a 
510/23nm band-pass filter for GFP and 600nm long-pass filter for TRITC. The 
fluorescence images were captured and recorded simultaneously through a cooled (-50°C) 
charge coupled device (CCD) digital camera (ORCA-ER, Hamamatsu Photonics) or 
high-sensitivity electron multiplier CCD (EM-CCD; ImagEM, Hamamatsu Photonics) 
camera controlled by AQUACOSMOS Imaging Station (Hamamatsu Photonics). We 
measured the fluorescence intensity of the GFP or TRITC in single granules. These values 
(F) were normalized to their initial values, F0 (ie. when the granules had docked but were 
still unopened) and the relative fluorescence change is referred to as F/F0. 
Cells transiently expressing GFP-tagged proteins were washed ×3 with HBS and 
incubated with fresh HBS for signal recording. Cells were kept at 37°C on the microscope 
stage (INUG2-ONID-BE, Tokai Hit, Shizuoka, Japan). In some experiments, a gravity-fed 
perfusion system was employed to exchange HBS for NH4Cl solution, Mes-buffered pH5.5 
solution or HBS containing PAI-1. The solutions were warmed at 37°C by an in-line 
heater with automatic temperature controller (Warner Instruments, CT, USA).  
 
Immunocytochemistry 
tPA-GFP-expressing or non-expressing-EA.hy926 cells cultured on a coverslip were fixed 
with 4% paraformaldehyde in PBS for 30min and permeabilized by 0.1% Triton X-100 for 
15min. After blocking with 2% bovine serum albumin, cells were stained with 5μg/ml 
anti-tPA for 1h, followed by Alexa Fluor 488 or TRITC-conjugated anti-IgG 
immunoglobulin (Molecular Probes, OR and Dako, CA) for 1h. After being mounted on a 
glass microscope slide with Dako fluorescent mounting medium, the specimens were 
examined by both epi- and TIR-F microscopy. 
 
Western blotting and fibrin autography 
Culture medium was collected after 1h or 24h and centrifuged at 3,000g for 10min to 
remove cell debris. It was then mixed with the sample buffer for SDS-PAGE. After 
separation by SDS PAGE, protein bands were trans-blotted onto a nitrocellulose 
membrane. tPA-, PAI-1- and GFP-related bands were then visualized by anti-tPA, 
anti-PAI-1 or anti-GFP antibody, followed by horseradish peroxidase (HRP)-conjugated 
second antibodies, using enhanced chemiluminescence (ECL) Western blotting detector 
reagents (Amersham Biosciences, UK). For fibrin autography, protein bands in the 
culture medium were similarly separated by SDS-PAGE, and tPA-dependent activity was 
detected by plasminogen-rich fibrin indicator gels as described previously.30 
 
Results 
tPA-GFP localizes in the secretory granules and is secreted into the medium in a 
functional form from VECs (EA.hy926 cells) 
We first characterized tPA-GFP expressed in EA.hy926 cells. Its intra-cellular localization 
was visualized by both epi- and TIR-F microscopy, and was compared to 
intrinsically-expressed tPA in EA.hy926 cells. The latter was detected by anti-tPA 
antibody labeled with FITC in small, round-shaped secretory granules (Fig 1A) as 
reported by Emeis et al in HUVECs.18 tPA-GFP fluorescence was detected in similar 
small granules in EA.hy926 cells. It was also detected by anti-tPA antibody labeled with 
TRITC, and its distribution in EA.hy926 cells was indistinguishable from intrinsically 
expressed tPA, which was more clearly and distinctly visualized by TIR-F (Fig 1B).  
We next characterized tPA-GFP enzymatic activity at 24h. in culture medium from either 
non-transfected EA.hy926 cells or those transfected with tPA-GFP expression vector. 
Western blot analysis (Fig 1C) using anti-tPA antibody revealed a high molecular weight 
band, approximately 147kDa, in culture medium from the tPA-GFP-expressing cells 
which was absent from controls. This band was also detected by anti-GFP antibody, 
suggesting that it corresponded to a tPA-GFP-PAI-1 complex. Bands corresponding to 
both free tPA-GFP and intrinsic tPA were not observed because of the high level of 
expression of PAI-1 in this cell line. The high molecular weight band was also visualized 
by fibrin zymography (Fig 1D), suggesting that tPA-GFP is enzymatically active, forming 
high molecular weight complexes with PAI-1 and developing lytic bands in 
plasminogen-rich fibrin gels. These results suggest that tPA-GFP was secreted in an 
active form into the supernatant from the granules which contained it, in the same way as 
the intrinsic tPA. Therefore, tPA-GFP appeared to be functional and thus to represent a 
suitable probe for investigating the secretory mechanism of tPA in VECs. 
 
Sequential steps (recruitment, docking, opening and release) of tPA-GFP secretory 
granular exocytosis are visualized by TIR-F microscopy. 
To investigate processes by which tPA-GFP was released from its secretory granules, we 
performed time-lapse analysis using TIR-F microscopy. This has the advantage that 
molecular events taking place near the plasma membrane can be analysed, and has been 
mainly applied to excitable cells.19-21 TIR-F illuminates to a depth ≤100 nm from the glass 
coverslip into the specimen because the energy wave drops off exponentially with distance 
from the coverslip-specimen interface. Using this technique, several sequential steps 
leading to single granular exocytosis of tPA-GFP were visualized as changes of 
fluorescence intensities. First, the recruitment of tPA-GFP-containing granules to the 
evanescent field and subsequent docking to the plasma membrane was imaged as the 
appearance of a static fluorescent spot. Second, granular opening was recognized as a 
sudden increase in fluorescence due mainly to neutralization of acidic pH in 
tPA-GFP-containing granules by culture medium at neutral pH. Indeed a spatial shift of 
tPA-GFP closer to the coverslip during granule opening also contributes to the increase in 
fluorescence. To confirm that the sudden increase in fluorescence does indeed represent 
the opening of tPA-GFP-containing granules, we analyzed simultaneous temporal profiles 
of fluorescence intensities of tPA-GFP and TRITC-conjugated anti-GFP antibody. Fig 2A 
shows that a sudden increase (arrow head) in green fluorescence of tPA-GFP 
corresponded to a gradual increase in red fluorescence, indicating that TRITC-conjugated 
anti-GFP antibody present in the extracellular space accumulated in the single opened 
granular spot. Every opened granule showed this gradual accumulation of red 
fluorescence (72 granules from 9 cells in 5 independent experiments). Evidently, sudden 
brightening of the secretory granule containing fluorescent tPA signifies the connection of 
the interior of the granule with the extracellular space. Third, the release of the contents 
of the granules was recognized by a decrease in fluorescence intensity. Because this third 
step is itself composed of several distinct steps, it will be described in detail later. Thus, 
we defined these three sequential main stages of changes in fluorescence intensity as 
reflecting the secretory process. 
   The third stage of the tPA-GFP secretory process, ie. cargo release into the 
extracellular space according to this definition, was more heterogeneous than the other 
two steps. To evaluate this, we attempted to estimate the kinetics of tPA-GFP release 
from opened granules. We calculated the time required for the fluorescence intensity to 
decline to half of its peak value during the exponential reduction period following the 
sudden brightening due to granule opening, which we designated TF1/2. The individual 
TF1/2 during the tPA-GFP releasing process varied widely from a maximum of 266 sec to a 
minimum of 1.13sec. This was analyzed and plotted for 77 granules in 10 cells (Fig 2B, C). 
Notably, almost all the fluorescent spots of exocytosed tPA-GFP, even those with the 
shortest TF1/2, remained detectable during the entire recording period (4.7min). Similar 
heterogeneity in the dynamics of fluorescent protein-labeled tPA release has also been 
described previously in bovine chromaffin cells31 and in insulin-producing MIN6 cells.32 
However, the underlying mechanisms and reasons for this have not yet been determined.  
 
tPA-GFP is retained on the membrane surface in a VEC-specific manner. 
The slow dimming of tPA-GFP fluorescence after granule opening was further analyzed. 
Several factors may contribute to this process: 1) diffusion of tPA-GFP from the site of the 
opened granule into the liquid-phase; 2) diffusion of tPA-GFP into the plasma membrane 
but retention at the membrane surface (lateral diffusion); and 3) recapturing (granule 
resealing) and re-acidification of tPA-GFP-containing granules. We first analyzed the 
latter possibility and asked whether the post-exocytotic spots of tPA-GFP is retained on 
the membrane surface. Taking advantage of GFP fluorescence quenching on acidification, 
we analyzed the effect of transiently exposing tPA-GFP-expressing EA.hy926 cells to 
Mes-buffered acidic pH solution (pH5.5 solution, applied three times for 30sec every five 
minutes). The degree of fluorescence of a granule which had brightened once on opening 
(Fig3A: arrowhead) and was then in the process of dimming, further decreased at pH5.5 
and was reversed on neutralization. This reversible dimming, detected as a relative 
fluorescence decrease >20% (Fig3B), persisted for as long as the fluorescent spots were 
detectable (tested on 67 granules in 6 cells, 5 independent experiments). This was longer 
than 5 minutes in 45 of these 67 granules (67%). In contrast, we also traced unopened 
granules at this time (albeit very few of them because of their motility) and found that 
their relative changes of fluorescence intensity were not influenced by expose to pH5.5 
(Fig3C: open triangles). These results indicate that the exocytosed tPA-GFP retained on 
the membrane surface during this observation period and that material is not recaptured. 
Further, we applied NH4Cl as a source of NH3 to tPA-GFP-expressing EA.hy926 cells. 
This penetrates the plasma membrane and neutralizes the acidic pH in intra-cellular 
organelles. Transient exposure to NH4Cl resulted in a 66.8±36.3% increase in fluorescence 
intensity of tPA-GFP (Fig 4B) before the secretory granule opened (Fig 4A: point b). Once 
the granule had opened, however, none of the 43 granules tested in 6 cells showed any 
significant increase in fluorescence intensity on NH4Cl exposure (Fig 4A: point f, Fig4B). 
This is in contrast to tPA-GFP expressed in insulin-producing MIN6 cells in which almost 
all the opened granules seemed to have been recaptured and re-acidified. When 
tPA-GFP-expressing MIN6 cells were depolarized by 40mM potassium followed by NH4Cl 
60-90 seconds later, the fluorescence intensity of 13 of 14 opened granules as well as 258 
unopened granules from 4 cells was increased (data not shown). These results indicate 
that the exocytosed tPA-GFP was retained at the membrane surface without retrieval for 
more than 5 minutes in a VEC-specific manner. The dimming of tPA-GFP fluorescence 
after granule opening appeared to result mainly from diffusion of tPA-GFP from the site 
of the opened granule membrane into either the fluid-phase and/or plasma membrane 
nearby in VECs. 
 
FnEK1K2 domains are responsible for binding of tPA-GFP to the membrane surface 
To investigate the mechanism of the slow release of tPA-GFP after exocytosis, we 
constructed a mutant tPA lacking the heavy chain and possessing only the signal peptides 
and catalytic domain and fused this with GFP (tPA-CD-GFP). The heavy chain of tPA is 
composed of finger, epidermal growth factor-like, kringle1, and kringle2 (FnEK1K2) 
domains (Fig 5A), and especially Fn and K2 domains play an important role in binding to 
fibrin clots.23 The intracellular distribution of tPA-CD-GFP was similar to wild-type 
tPA-GFP in both epi-F and TIR-F microscopy imaging (Fig 5B). In wild-type, the 
reduction in fluorescence after rapid brightening in opened single secretory granules was 
slow (Movie 1: tPA-GFP at 1Hz). In contrast, tPA-CD-GFP fluorescence disappeared 
immediately after opening, like a flashlight being turned off, and did not leave any 
fluorescent spots of post-exocytotic tPA-CD-GFP (Movie 2: tPA-CD-GFP at 1.4Hz). When 
NH4Cl solution was transiently applied to tPA-CD-GFP-expressing cells, all granule spots 
in the TIR-F area increased in brightness (270 granules in 6 cells), suggesting that 
tPA-CD-GFP molecules were not retained on the membrane surface but were present only 
in unopened granules. These results indicate that tPA-CD-GFP could not be retained on 
the membrane surface because of the lack of the FnEK1K2 domain. The reduction in 
fluorescence after opening in domain-deletion mutants of either Fn or K2 of tPA-GFP 
expressing cells was also faster than that in wild-type (Fig S1), suggesting the importance 
of these domains in the binding.  
   To evaluate the rapid discharge of tPA-CD-GFP, we acquired images with a highly 
sensitive electron multiplier CCD (EM-CCD) camera to improve time resolution. Fig 5C 
shows the 32 frames per second (fps)-sequences of tPA-CD-GFP discharge from a single 
granule. After granule opening shown at time 0 ms, fluorescence diffused and had mostly 
disappeared by 250ms. In this short period of time, in contrast, the fluorescence of 
exocytosed wild-type tPA-GFP remained strong (Fig 5D). The rapid time course of 
disappearance of tPA-CD-GFP was similar to the exocytotic time course of neuropeptide Y 
(NPY)-GFP in PC12 cells.33 Therefore, FnEK1K2 domains appeared responsible for the 
binding of exocyotosed tPA-GFP to the membrane surface as well as for the heterogeneous 
dynamics of the tPA release process. 
 
PAI-1 accelerates membrane surface-retained tPA dissociation 
Because tPA-GFP as well as intrinsic tPA was observed only as a complex with PAI-1, and 
essentially no free form was detected in the supernatant, we investigated the effects of 
PAI-1 on the dynamics of tPA release using three different approaches, i) supplementation 
with recombinant PAI-1 ii) use of a GFP tagged mutant form of tPA, tPA-S478A-GFP iii) 
suppression of PAI-1 synthesis by siRNA. In the first approach, we analyzed the effect of 
recombinant PAI-1 (rPAI-1) in tPA-GFP-expressing EA.hy926 cells. TF1/2 values before 
and after the addition of 40nM rPAI-1 were calculated. Although the frequency of granule 
opening during each of the 4.7minute observation periods was similar (53 granules before 
addition and 55 granules after addition opened in 6 cells, 4 independent experiments), 
TF1/2 was significantly reduced on addition of 40nM rPAI-1 (Fig 6A). This accelerated 
reduction in fluorescence intensity in post-exocytotic spots after rPAI-1 treatment was 
also detected even after pretreatment with 400nM receptor associated protein (RAP) 
which antagonizes the binding of tPA and tPA-PAI-1 complex to the low-density 
lipoprotein receptor-related protein (LRP) (Fig 6C). When the cells were incubated with 
rPAI-1 for 60min, tPA increased in a dose-dependent manner in the supernatant only in 
the form of a complex with rPAI-1, as detected by fibrin autography (Fig 6B). PAI-1 
appeared to facilitate the dissociation not only of tPA-GFP but also intrinsic tPA from the 
granule membrane surface by forming high molecular weight complexes. In the second 
approach, we constructed a GFP-tagged mutant form of tPA, tPA-S478A, in which Ser 478 
was substituted by Ala so as to be catalytically inactive and unable to form covalent 
complexes with PAI-1, and analyzed its exocytotic dynamics. Although the efficacy of 
expression of tPA-S478A-GFP and wild-type tPA-GFP was similar, the former did not 
appear in the culture medium after 24h. either complexed with PAI-1 or in the free form 
(Fig 7A). The intracellular distribution of tPA-S478A-GFP and tPA-GFP was 
indistinguishable, as judged by epi-F. In contrast, however, TIR-F revealed much stronger 
fluorescence of tPA-S478A-GFP than wild-type (Fig 7B), suggesting that it is present at 
higher concentrations near the plasma membrane. The secretory dynamics of 
tPA-S478A-GFP also differ from wild-type (Movie 3), and it remained attached to the 
membrane surface for a longer period of time after granules’ opening. Eventually it did 
diffuse away into the plasma membrane, because strong fluorescence was observed not 
only in secretory granular spots but also in the surrounding plasma membrane. The 
presence of large amounts of tPA-S478A-GFP on the exterior plasma membrane was 
further confirmed by the fact that the decreasing intensity of fluorescence in whole cells 
measured by epi-F image (dFcell) was more pronounced for tPA-S478A-GFP than wild-type 
when cells were exposed to pH5.5 solution (Fig 7C). Lack of formation of high molecular 
weight complexes between tPA-S478A-GFP and PAI-1 seems to render detachment from 
the membrane surface difficult, which eventually resulted in its accumulation on the cell 
surface. Accordingly, exogenous PAI-1 did not affect the prolonged TF1/2 in single granules 
containing tPA-S478A-GFP (Fig 7D, gray bars). In the third approach, in order to more 
clearly demonstrate the effect of exogenous rPAI-1 on membrane surface-retained tPA, 
EA.hy926 cells were treated with PAI-1 siRNA to negate the effects of intrinsically 
synthesized PAI-1. Transient transfection with two different sequences (#1, #4) of 20nM 
PAI-1 siRNA reduced the amount of free PAI-1 in the culture medium after 18 h, although 
complexes with tPA did not change a great deal (Fig 7E). Under such conditions, TF1/2 was 
prolonged significantly in comparison with control siRNA transfected cells (#1: 23.9±3.56s 
from 141 granules, #4: 23.0±4.80s from 40 granules vs. control siRNA: 8.1±0.47s from 113 
granules, p<0.001 respectively, data given as means±S.E.) (Fig 7F). These effects of PAI-1 
siRNA were prevented by the addition of 40nM rPAI-1 (Fig 7G), reverting to the values for 
non-treated EA.hy926 cells as shown in Fig6A. PAI-1, therefore, appeared to regulate the 
amounts of cell surface-associated tPA on VECs by facilitating the dissociation of tPA from 
the cell surface. 
 
Discussion 
Here, we demonstrated unique, slow secretory dynamics of tPA in VECs. In EA.hy926 
cells, tPA-GFP was retained as fluorescent spots on the membrane surface after secretory 
granule opening without any internalization for more than five minutes. This contrasts 
with the exocytotic dynamics of tPA-containing secretory granules in endocrine and 
neuronal cells where post-exocytotic tPA granules are retrieved, as described by 
“kiss-and-run” or “cavicapture” models.21,31-34 In the present study, we showed for the first 
time that the FnEK1K2 domains in tPA molecule are responsible for the retention of 
exocytosed tPA on the cell surface. Retention of the active form of tPA on the cell surface 
without retrieval may be beneficial for maintaining high fibrinolytic activity. Further, 
employing three different approaches, we demonstrated that PAI-1, the primary inhibitor 
of tPA, facilitates tPA dissociation from the VEC surface and functions as principal 
determinant of fibrinolytic activity on VECs as well as in plasma. 
   A unique characteristic of the tPA releasing process in VECs is the extended period 
during which exocytosed tPA is retained on the surface of the cell without either retrieval 
or internalization. This was confirmed by two distinct experiments. One is the quenching 
of fluorescence of tPA-GFP spots by transient application of pH5.5 solution to 
tPA-GFP-expressing EA.hy926 cells. The quenching was only observed in the spots which 
had already opened and persisted for as long as the fluorescent spots were detected. 
Another finding, that RAP did not modify the kinetics of the disappearance of tPA-GFP 
from the membrane may suggest that the internalization of tPA or tPA-PAI-1 through 
LRP is not the major mechanism mediating tPA disappearance from the membrane 
surface.  
   In VECs, exocytosis mechanisms have been intensively studied35-37 in another large 
rod-shaped regulated secretory granules, known as Weibel-Palade bodies (WPBs). WPBs 
contain von Willebrand factor (vWF), endothelin, interleukin-8, and several adhesion 
molecules like P-selectin and CD63. Romani de Wit et al. assessed the trafficking of WPBs 
during signal-mediated exocytosis in living vWF-GFP-infected HUVECs and showed that 
the granules were retained as extracellular patches after opening evoked by both Ca2+ 
and cAMP-mobilizing agonists.38 Similarly to our present results on tPA-GFP-containing 
granules, individual vWF-GFP patches remained visible for ~20min.39 Although the 
precise mechanisms responsible for these phenomena have not been clarified yet, such 
sustained retention of cargos after exocytosis appear common to both tPA and vWF in 
VECs. 
   When a mutant tPA-GFP lacking FnEK1K2 domains (tPA-CD-GFP) was employed, 
the fluorescence disappeared in as short as 250ms without leaving any fluorescent spots. 
This confirms that FnEK1K2 domains are responsible for the retention of tPA molecules 
on the membrane. tPA is known to bind to fibrin and denatured proteins having cross beta 
structures,40 and to efficiently catalyze plasminogen activation in which finger and K2 
domains, are reported to be responsible.41 The K2 domain possesses so-called lysine 
binding sites (LBS), and binds to proteins bearing C-terminal lysine either on cell 
membranes or in plasma. It now appears that FnEK1K2 domains, especially finger and 
K2 domains, are also responsible for the retention of post-exocytotic tPA molecules on the 
cell surface. 
   Although the FnEK1K2 domains of the tPA molecule are responsible for its retention 
on the membrane surface, no plasma membrane-associated tPA binding factor has been 
identified in the present study. Among several proteins known to bind to tPA,42 annexin 
A2 is a particularly good candidate because it binds both tPA and plasminogen, and 
thereby facilitates plasmin generation on the endothelial cell surface.43,44 In most 
previous studies, however, direct interactions between annexin A2 and intrinsically 
generated and exocytosed tPA, were not investigated. We analyzed possible binding of 
exocytosed tPA-GFP to annexin A2 on the surface of EA.hy926 cells. However, we failed to 
demonstrate colocalization of tPA-GFP with intrinsically generated annexin A2 either by 
immunocytochemistry or by using monomeric red fluorescent protein (mRFP)-tagged 
annexin A2 in EA.hy926 cells (data not shown). We hypothesize, therefore, that de novo 
synthesized tPA is present in the secretory granules and/or membrane surface bound via 
FnEK1K2 domains to unidentified factors other than annexin A2 even after exocytosis. 
Another possibility that exocytosed tPA binds to the matrix in the localized area is also 
not excluded, and further study is needed to identify the binding factor for tPA. 
   This sustained retention of tPA may be beneficial for maintaining functional 
fibrinolytic activity, because the secreted single-chain tPA is enzymatically active8 and the 
VEC surface is the site where fibrinolytic components assemble and mediate their 
functions.7 We successfully demonstrated the cell surface-retained intrinsic tPA activity 
after suppression of PAI-1 synthesis by siRNA transfection in EA.hy926 cells, which was 
totally inhibited by supplemented rPAI-1 (FIG S2). PAI-1 seems to suppress tPA activity 
not only in the fluid phase but also in solid-phase structures, on the cell surface, by 
facilitating the dissociation of membrane-retained intrinsic tPA. The facilitated 
dissociation of tPA-GFP by supplemental rPAI-1 was more clearly shown when intrinsic 
PAI-1 synthesis was suppressed by siRNA, suggesting that disappearance of tPA-GFP, 
which was slow as shown in the present study, was still under the control of intrinsically 
generated PAI-1 in EA.hy926 cells. Another finding, that tPA-S478A-GFP stayed on the 
cell membrane for a long period, suggests that PAI-1 is the principle modifier of both the 
duration and amount of tPA retained on the cell membrane. This notion is in agreement 
with a well-established concept that elevated plasma PAI-1 levels, mainly due to obesity 
and insulin resistance, are risk factors for cardiovascular events.45 Decreased amounts of 
tPA retained at the VEC surface because of an excess of PAI-1 in plasma is one possible 
mechanism of hypo-fibrinolysis under pathological conditions.   
   As well as their ability to secrete tPA, VECs perform a variety of functions that 
regulate vascular tone, coagulation, fibrinolysis and inflammation. VEC dysfunction is 
characterized by vasoconstriction, thrombus formation, impaired fibrinolysis and 
expression of adhesion molecules. Oliver et al. reviewed9 the complexity of vascular 
biology in VEC dysfunction and concluded that some conditions associated with reduced 
tPA release are not necessarily accompanied by impaired endothelium-dependent 
vasodilation. They also discuss the possibility that under certain circumstances, reduced 
tPA release may be a more sensitive marker of endothelial dysfunction than 
endothelium-dependent vasomotion, for example in smokers and patients with 
hypertension. To date, tPA release is only recognized by an increase in tPA concentration 
in plasma. However, tPA retention time on the cell surface, defined here as TF1/2, would 
reflect fibrinolytic potency more directly than plasma tPA, and might also be an 
important indicator of VEC function. Evaluating tPA retention time in controlled 
secretion induced by various agonists including shear stress will be required to verify its 
significance for VEC function. 
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Figure legends 
 
Figure 1. Properties of tPA-GFP expressed in EA.hy926 cells. Intracellular localization of intrinsic tPA (A) and forcibly 
expressed tPA-GFP (B) in confluent EA.hy926 cells analyzed by immunofluorescence staining and represented by both 
epi-fluorescence (epi-F) and total internal reflection fluorescence (TIR-F) images. Fig. 1A: intrinsically expressed tPA 
molecules in EA.hy926 cells detected by anti-tPA antibody together with Alexa Fluor 488-labeled anti-IgG. Fig. 1B: 
tPA-GFP (upper panels) and tPA-related proteins detected by anti-tPA antibody together with TRITC-labeled anti-IgG 
(middle panels). The lower panels are the merged images of the upper-and middle-panels. The bars represent 10 μm. (C) 
Western blotting of 24 h culture media from untransfected cells or transfected with tPA-GFP expression vector. Protein 
bands were detected by either anti-tPA or anti-GFP antibody. (D) The same samples in (C) were also analyzed by 
plasminogen-rich fibrin autography. M: molecular weight markers for 201, 120, 100, and 56 kDa, respectively, R: a 
mixture of recombinant tPA and recombinant PAI-1, filled arrowheads: tPA-PAI-1 complexes, open arrowheads: free tPA. 
Extra high molecular weight bands in culture medium from tPA-GFP-expressing cells (arrows) were detected by both 
anti-tPA and anti-GFP antibodies, and developed lytic bands in fibrin autography. 
 
Figure 2. Secretory kinetics of tPA-GFP determined by TIR-F microscopy. (A) Secretory kinetics of tPA-GFP in 
EA.hy926 cells analyzed by TIR-F microscopy using recording medium containing 50 μg/ml TRITC-conjugated anti-GFP 
antibody. Changes in the fluorescence intensities of both GFP and TRITC were monitored simultaneously through 
W-View system at 1.4 Hz. The means ± S.D. of relative changes in fluorescence intensity (F/F0) of tPA-GFP (filled circles) 
and TRITC-conjugated anti-GFP antibody (open triangles) in 72 granules from 9 cells tested are shown in A (5 
independent experiments). Sudden increase in green fluorescence (arrowhead) was followed by a gradual increase in red 
fluorescence. (B) Individual TF1/2 (the time required for the fluorescence to decline to half of its peak value) which 
defines the half-life of exocytosed tPA-GFP disappearance from the membrane surface are plotted (77 granules in 10 
cells). Expanded time points within 50-second TF1/2 are shown in the inset. (C) Number of total occurrences calculated 
for individual TF1/2 (abscissa) shown as percentages of total occurrences (ordinate). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3 
 
Figure 3. Effects of perfusion of Mes-buffered pH 5.5 solution on the fluorescence intensity of tPA-GFP after opening of 
the granules. (A) tPA-GFP-expressing EA.hy926 cells were perfused with Mes-buffered pH 5.5 solution for 30 sec every 
5 min, 3 times. Representative data on the relative changes in fluorescence intensity (F/F0) of tPA-GFP in one single 
secretory granule at 1.4 Hz are shown. Application of pH 5.5 solution (dashed box) caused an abrupt decrease in GFP 
fluorescence intensities after exocytosis, which was quickly recovered on neutralizing the pH (HBS). Arrowhead 
indicates opening of the granule. Similar fluctuations were observed even at the second application of the pH 5.5 
solution in 45 of 67 granules (67%) in 5 independent experiments. (B) Abscissa: time after granule opening before 
application of pH 5.5 solution, Ordinate: percent decrease in relative fluorescence intensity in individual granules after 
application of pH 5.5 solution. Mean ± S.D. in each time category from 126 events of pH 5.5 application in 67 opened 
granules. (C) Expanded graph of (A) at the 1st application of pH 5.5 solution. Application of pH 5.5 solution triggered 
the decrement of GFP fluorescence in postexocytotic spots (filled circles), but did not significantly change this in 
unopened granules (open triangles, mean ± S.E. from 6 granules).  
 
 
 
 
 
Figure 4. Effects of perfusion of NH4Cl solution on the fluorescence intensity of tPA-GFP before and after opening of the 
granules. (A) tPA-GFP-expressing cells exposed to 50 mM NH4Cl solution (dashed box). Representative data on F/F0 of 
tPA-GFP secretory granules either opened (filled circles, granule I, opened at time “d”) and not opened (open triangles, 
granule II) at 1.4 Hz. Upper panels: images of whole cell at point d (opening, arrowhead) and f (NH4Cl exposure). The 
bar represents 10 μm. Middle panels (a-g): images taken at the times indicated by the arrows from opened (I) and 
unopened (II) granules. Brief application of NH4Cl increased fluorescence intensity of tPA-GFP in unopened granules (I 
at time “b”, II at time “f”), but not opened granules (I at time “f”). (B) Percent increase in relative fluorescence intensity 
from 111 unopened and 43 opened tPA-GFP containing granules in 6 cells on NH4Cl exposure. 5 independent 
experiments are shown as mean ± S.D. In the analysis of opened granules, the mean time after granule opening to 
NH4Cl exposure was 5.85 minutes. 
 
 
 
 
 
 
Figure 5. High time-resolution analysis of the secretory dynamics of tPA-CD-GFP. (A) molecular structure of tPA (B) 
epi-F and TIR-F images in tPA-CD-GFP-expressing cells. The bars represent 10 μm. (C) Representative 32 frames per 
second-sequences of the single tPA-CD-GFP secretory granule indicated by a white box in A. Time 0 shows the point of 
granule opening. (D) Changes in F/F0 in each single secretory granule plotted as a function of the time after opening 
(time 0) of tPA-CD-GFP-containing granules (filled triangles, 31 granules from 6 cells) compared to tPA-GFP-containing 
granules (filled circles, 8 granules from 3 cells). Data are shown as mean ± S.E. 
 
 
 
 
 
 
 
 
 
 
Figure 6. The effect of recombinant PAI-1 on membrane surface-retained tPA. (A) TF1/2 values of tPA-GFP (abscissa) 
before (filled bars: 53 granules) and after (open bars: 55 granules) addition of 40 nM recombinant PAI-1 (6 cells, 4 
independent experiments) shown as percentages of total occurrences (ordinate). Exogenous PAI-1 increased the 
frequency of rapidly disappearing fluorescence having short TF1/2. (B) Fibrin autography of the supernatants of the cells 
incubated with exogenous rPAI-1 at 0, 10, 40 nM for 60 min. The amounts of tPA increased as a function of the amounts 
of added PAI-1, in the form of a tPA-PAI-1 complex in the supernatant. A representative image from five independent 
experiments is shown. (C) TF1/2 values of tPA-GFP (abscissa) before (filled bars: 89 granules), after incubation with 
400nM RAP (gray bars: 80granules) and after further addition of 40 nM recombinant PAI-1 (open bars, 76 granules) 
from 6 independent experiments shown as percentages of total occurrences (ordinate). The presence of RAP did not 
change the effect of PAI-1 as shown in (A). 
 
 
 
 
 
  
 Figure 7. Secretory dynamics of tPA-S478A-GFP (A-D) and tPA-GFP in PAI-1 siRNA transfected cells (E-G). (A) 24 h. 
culture media from tPA-GFP-expressing (wild-type) or tPA-S478A-GFP-expressing (S478A) cells analyzed by Western 
blotting using anti-tPA antibody antibody. M: molecular weight markers for 201, 120, 100, and 56 kDa, respectively, 
filled arrowheads: tPA-PAI-1 complex. Additional high molecular weight bands of tPA-GFP-PAI-1 complexes (arrows), 
which reacted anti-tPA antibody, were only detected in culture media from tPA-GFP-expressing cells. (B) epi-F and 
TIR-F images in tPA-GFP- and tPA-S478A-GFP-expressing cells. tPA-S478A-GFP appeared diffusely distributed over 
the membrane surface as shown in the TIR-F image. The bars represent 10 μm. (C) Cells expressing either tPA-GFP 
(wild-type, 11 cells) or tPA-S478A-GFP (S478A, 13 cells) exposed to Mes-buffered low pH solution for 1 min, and the 
decrease in relative fluorescence intensity in a whole cell measured by epi-F image (dFcell) calculated. Decrease in 
fluorescence intensity was significantly greater in tPA-S478A-GFP cells than tPA-GFP cells. Data are shown as mean ± 
S.D. (D) TF1/2 values (abscissa) in tPA-GFP (filled bars, 77 granules in 10 cells), tPA-S478A-GFP (open bars, 54 granules 
in 7 cells) and tPA-S478A-GFP supplemented with 40 nM rPAI-1 (gray bars, 12 granules in 2 cells) shown as 
percentages of total occurrences (ordinate). Exogenous PAI-1 did not modify the slow disappearance having long TF1/2 in 
tPA-S478A-GFP-expressing cells. (E) 18 h. culture media from siRNA (PAI-1 #1, #4 and control) transfected cells 
analyzed by Western blotting using anti-PAI-1 antibody. R: mixture of recombinant tPA-PAI-1 complexes and free PAI-1. 
(F) TF1/2 values (abscissa) of tPA-GFP in control siRNA (open bars, 113 granules in 8 cells, 5 experiments), PAI-1 siRNA 
#1 (filled bars, 141 granules in 10 cells, 5 experiments) and PAI-1 siRNA #4 (gray bars, 40 granules in 3 cells, 3 
experiments) treated cells, shown as percentages of total occurrences (ordinate). (G) TF1/2 values (abscissa) of tPA-GFP 
before (filled bars, 66 granules) and after (open bars, 30 granules) addition of 40 nM rPAI-1 in PAI-1 siRNA #1 or #4 
transfected cells (3 experiments) shown as percentages of total occurrences (ordinate). Exogenous PAI-1 increased the 
frequency of rapid disappearing granules having short TF1/2. 
